Shattuck Labs (STTK)
Develops DR3-blocking antibodies for inflammatory and immune-mediated diseases.
Something off on this page? Send us feedback.
Develops DR3-blocking antibodies for inflammatory and immune-mediated diseases, led by SL-325 for inflammatory bowel disease and supported by a DR3-based bispecific program. Operating resources are concentrated on clinical development of this narrow pipeline from Austin and Durham.
Develops DR3-blocking antibodies for inflammatory and immune-mediated diseases, led by SL-325, a monoclonal antibody for inflammatory bowel disease. A DR3-based bispecific effort, including SL-846, extends the same pathway strategy.
Operates from Austin and Durham with research centered on protein engineering, TNF-receptor biology, and blockade of TL1A/DR3 signaling. The current portfolio reflects a 2024 reset that discontinued the former oncology lead and concentrated resources on DR3 programs.
At this clinical stage, progress depends on trial results, regulatory decisions, and continued financing. The narrow pipeline makes SL-325 development and expansion into bispecific antibodies central to the business.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 24, 2026 | Raymond James | Initiate | Strong Buy | $18 | ||
| Aug 11, 2026 | H.C. Wainwright | Reiterate | Buy | $18 | $14 | |
| Jul 20, 2026 | Leerink Partners | Target | $2 | $16 | ||
| Jun 5, 2026 | Jefferies | Target | $7 | |||
| Jun 5, 2026 | Citigroup | Upgrade | Neutral | Buy |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $63.3M · Total debt $2.7M · Total assets $220.7M · Shareholders' equity $211.1M
- Revenue
- $0
- Operating income
- −$16.2M
- Net income
- −$15.2M
No dividends on record.
| Institutions83 holders · as of Mar 31, 2026 | 55.87% | 56.07M shares | |
| Insiders7 holders · as of Jul 7, 2026 | 1.13% | 1.13M shares | |
| Strategic holders1 holder · as of Jun 17, 2026 | 4.98% | 5.00M shares | |
| Otherremainder | 38.02% | 38.16M shares |
100.36M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (100.36M in the company's Sep 3, 2026 report, 90.37M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
T. Rowe Price Investment Management, Inc.Institution | 9.83% | 9.87M | 13Fas of Mar 31, 2026 |
Orbimed Advisors LLCInstitution | 6.28% | 6.31M | 13Fas of Mar 31, 2026 |
Redmile Group, LLCInstitution | 5.52% | 5.54M | 13Fas of Mar 31, 2026 |
Prosight Management, LPInstitution | 4.99% | 5.00M | 13Fas of Mar 31, 2026 |
Deep Track Capital, LPStrategic | 4.98% | 5.00M | 13Gfiled Jun 17, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 2, 2026 | Abhinav A. Shukla | officer: Chief Technical Officer | −410 | $7.01 |
| Jun 30, 2026 | Arundathy N. Pandite | officer: Chief Medical Officer | −30,000 | $7.01 |
| Jun 30, 2026 | Abhinav A. Shukla | officer: Chief Technical Officer | −23,365 | $7.08 |
| Jul 1, 2026 | Abhinav A. Shukla | officer: Chief Technical Officer | −100 | $7.07 |
| Jun 11, 2026 | Orbimed Advisors LLC | director | +1,250,000 | $0.0001 |
- Merck
Phase 3 anti-TL1A leader in Crohn’s disease and ulcerative colitis
- Teva (ADR)
Phase 3 anti-TL1A program co-developed with Sanofi for Crohn’s and UC
- Spyre Therapeutics
Phase 2 anti-TL1A and antibody-combination rival in IBD
- Xencor
Phase 2b anti-TL1A and planned dual-pathway clinical rival
- AbbVie
Phase 1 anti-TL1A entrant for inflammatory bowel disease
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Shattuck Labs | $6.98 | +1.01% | $624.5M | — | — | 624.5 | −66.6% |
| Merck | $151.86 | +0.15% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Teva (ADR) | $37.30 | −0.45% | $43.66B | 62.5 | 13.3 | 2.4 | −0.8% |
| Spyre Therapeutics | $86.71 | −0.44% | $7.56B | — | — | 83.5 | — |
| Xencor | $27.00 | +0.37% | $1.99B | — | — | 19.0 | +17.5% |
| AbbVie | $261.54 | −0.06% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Median | 73.7 | 17.2 | 7.2 | +7.6% |